Terminated PHASE1 INTERVENTIONAL 1-arm NCT00048100

Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes

Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes for Therapy of Relapsed Leukemia After Allogeneic Stem Cell Therapy

Sponsor: M.D. Anderson Cancer Center

Conditions Leukemia, Myelocytic, Acute

Interventions Apheresis Stem Cell Transplant

Updated 7 times since 2017 Last updated: Oct 30, 2018 Started: Feb 28, 2001 Primary completion: May 31, 2005 Completion: May 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow accrual.

Other terminated trials from M.D. Anderson Cancer Center

See all terminations from M.D. Anderson Cancer Center

A PHASE1 clinical study on Leukemia, Myelocytic, Acute, this trial is terminated or withdrawn. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 7 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Nov 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jun 2018 — Nov 2018 [monthly]

Terminated PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Feb 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States